Journal Home > Volume 8 , Issue 2
Food Science and Human Wellness 2019, 8(2): 83-95 https://doi.org/10.1016/j.fshw.2019.03.006
Review Article | Open Access | Issue | Published: 28 March 2019

Diet and medical foods in Parkinson's disease

Show Author's Information Klaus W. Langea( ),  Yukiko Nakamuraa,  Ning Chenb,  Jianjun Guoc,  Shigehiko Kanayad,  Katharina M. Langee,  Shiming Lif
Department of Experimental Psychology, University of Regensburg, Regensburg, Germany
Tianjiu Research and Development Center for Exercise Nutrition and Foods, Hubei Key Laboratory of Exercise Training and Monitoring, College of Health Science, Wuhan Sports University, Wuhan, China
China Institute of Sport Science, Beijing, China
Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
Department of Psychology, University of Winchester, Winchester, United Kingdom
Department of Food Science, Rutgers University, New Brunswick, NJ, USA
Keywords:
Prevention, Diet, Probiotics, Parkinson's disease, Ketogenic diet, Medical food
Cite this article:
Lange KW, Nakamura Y, Chen N, et al. Diet and medical foods in Parkinson's disease. Food Science and Human Wellness, 2019, 8(2): 83-95. https://doi.org/10.1016/j.fshw.2019.03.006
Download citation
EndNote(RIS)
BibTeX

886

Views

52

Downloads

Citations

20

Crossref

N/A

WoS

21

Scopus

0

CSCD

Abstract Full text About this article

Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder with motor and non-motor signs, which begins long before the diagnosis can be made. Pharmacotherapy with dopaminergic drugs is the mainstay of PD therapy. There is no currently available cure or disease-modifying treatment. Diet and various foods have been proposed as possible risk factors for PD. Nutritional supplementation with omega-3 fatty acids, vitamin D, B vitamins, and coenzyme Q may have potential in the management of PD. In addition, several strategies could possibly lead to the development of medical foods in PD. For example, ketogenic diets may have effects complementary to pharmacotherapy. Gut microbial dysbiosis and altered microbial metabolites found in PD may lead to chronic low-grade inflammation in gut and brain. Interventions targeting gut microbiota, such as the supplementation of probiotics, may provide novel approaches to PD in regard to both symptomatic treatment and disease modification. High quality randomized controlled trials need to be conducted in order to evaluate whether these food-based strategies have symptomatic efficacy or the potential to delay the progression of PD.


menu
Abstract
Full text
Outline
About this article

Diet and medical foods in Parkinson's disease

Show Author's information Klaus W. Langea( ), Yukiko Nakamuraa, Ning Chenb, Jianjun Guoc, Shigehiko Kanayad, Katharina M. Langee, Shiming Lif
Department of Experimental Psychology, University of Regensburg, Regensburg, Germany
Tianjiu Research and Development Center for Exercise Nutrition and Foods, Hubei Key Laboratory of Exercise Training and Monitoring, College of Health Science, Wuhan Sports University, Wuhan, China
China Institute of Sport Science, Beijing, China
Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma, Japan
Department of Psychology, University of Winchester, Winchester, United Kingdom
Department of Food Science, Rutgers University, New Brunswick, NJ, USA

Abstract

Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder with motor and non-motor signs, which begins long before the diagnosis can be made. Pharmacotherapy with dopaminergic drugs is the mainstay of PD therapy. There is no currently available cure or disease-modifying treatment. Diet and various foods have been proposed as possible risk factors for PD. Nutritional supplementation with omega-3 fatty acids, vitamin D, B vitamins, and coenzyme Q may have potential in the management of PD. In addition, several strategies could possibly lead to the development of medical foods in PD. For example, ketogenic diets may have effects complementary to pharmacotherapy. Gut microbial dysbiosis and altered microbial metabolites found in PD may lead to chronic low-grade inflammation in gut and brain. Interventions targeting gut microbiota, such as the supplementation of probiotics, may provide novel approaches to PD in regard to both symptomatic treatment and disease modification. High quality randomized controlled trials need to be conducted in order to evaluate whether these food-based strategies have symptomatic efficacy or the potential to delay the progression of PD.

Keywords: Prevention, Diet, Probiotics, Parkinson's disease, Ketogenic diet, Medical food

References(236)

[1]

E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, C.M. Tanner, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology 68 (2007) 384-386.
DOI Google Scholar
[2]

E.C. Hirsch, A.M. Graybiel, Y. Agid, Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease, Nature 334 (1988) 345-348.
DOI Google Scholar
[3]
J. Parkinson, An Essay on The Shaking Palsy, Sherwood, Neely and Jones, London, 1817.
[4]

C.D. Marsden, Parkinson's disease, Lancet 335 (1990) 948-952.
DOI Google Scholar
[5]

K.W. Lange, T.W. Robbins, C.D. Marsden, M. James, A.M. Owen, G.M. Paul, L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction, Psychopharmacology 107 (1992) 394-404.
DOI Google Scholar
[6]

A.M. Owen, M. James, P.N. Leigh, B.A. Summers, C.D. Marsden, N.P. Quinn, K.W. Lange, T.W. Robbins, Fronto-striatal cognitive deficits at different stages of Parkinson's disease, Brain 115 (1992) 1727-1751.
DOI Google Scholar
[7]

K.W. Lange, G.M. Paul, M. Naumann, W. Gsell, Dopaminergic effects on cognitive performance in patients with Parkinson's disease, J. Neural Transm. Suppl. 46 (1995) 423-432.
Google Scholar
[8]

S.S. O'Sullivan, D.R. Williams, D.A. Gallagher, L.A. Massey, L. Silveira-Moriyama, A.J. Lees, Non motor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study, Mov. Disord. 23 (2008) 101-106.
DOI Google Scholar
[9]

K.R. Chaudhuri, A.H.V. Schapira, Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, Lancet Neurol. 8 (2009) 464-474.
DOI Google Scholar
[10]

R. Savica, W.A. Rocca, J.E. Ahlskog, When does Parkinson disease start? Arch. Neurol. 67 (2010) 798-801.
DOI Google Scholar
[11]

R.B. Postuma, D. Aarsland, P. Barone, D.J. Burn, C.H. Hawkes, W. Oertel, T. Ziemssen, Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease, Mov. Disord. 27 (2012) 617-626.
DOI Google Scholar
[12]

H. Braak, U. Rüb, W.P. Gai, K. Del Tredici, Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen, J. Neural Transm. 110 (2003), 517–S36.
DOI Google Scholar
[13]

M.C. de Rijk, L.I. Launer, K. Berger, M.M. Breteler, J.F. Dartigues, M. Baldereschi, L. Fratiglioni, A. Lobo, J. Martinez-Lage, C. Trenkwalder, A. Hofman, Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts, Neurology 54 (Suppl. 5) (2000) S21-S23.
Google Scholar
[14]

R. Inzelberg, E. Schechtman, D. Paleacu, Onset age of Parkinson disease, Am. J. Med. Genet. 111 (2002) 459-460.
DOI Google Scholar
[15]

U.B. Muthane, H.S. Swamy, P. Satishchandra, M.N. Subhash, S. Rao, D. Subbakrishna, Early onset Parkinson's disease: are juvenile- and young-onset different? Mov. Disord. 9 (1994) 539-544.
DOI Google Scholar
[16]

L.I. Golbe, Young-onset Parkinson's disease: a clinical review, Neurology 41 (1991) 168-173.
DOI Google Scholar
[17]

J.A. Obeso, M.C. Rodriguez-Oroz, C.G. Goetz, C. Marin, J.H. Kordower, M. Rodriguez, E.C. Hirsch, M. Farrer, A.H. Schapira, G. Halliday, Missing pieces in the Parkinson's disease puzzle, Nat. Med. 16 (2010) 653-661.
DOI Google Scholar
[18]

B. Halliwell, Reactive oxygen species and the central nervous system, J. Neurochem. 59 (1992) 1609-1623.
DOI Google Scholar
[19]

E. Sofic, K.W. Lange, K. Jellinger, P. Riederer, Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease, Neurosci. Lett. 142 (1992) 128-130.
DOI Google Scholar
[20]

S. Bharath, M. Hsu, D. Kaur, S. Rajagopalan, J.K. Andersen, Glutathione, iron and Parkinson's disease, Biochem. Pharmacol. 64 (2002) 1037-1048.
DOI Google Scholar
[21]

M. Deleidi, T. Gasser, The role of inflammation in sporadic and familial Parkinson's disease, Cell. Mol. Life Sci. 70 (2013) 4259-4273.
DOI Google Scholar
[22]

L.M. de Lau, M.M. Breteler, Epidemiology of Parkinson's disease, Lancet Neurol. 5 (2006) 525-535.
DOI Google Scholar
[23]

K. Wirdefeldt, H.O. Adami, P. Cole, D. Trichopoulos, J. Mandel, Epidemiology and etiology of Parkinson's disease: a review of the evidence, Eur. J. Epidemiol. 26 (Suppl. 1) (2011) S1-S58.
DOI Google Scholar
[24]

L. Fleming, J.B. Mann, J. Bean, T. Briggle, J.R. Sanchez-Ramos, Parkinson's disease and brain levels of organochlorine pesticides, Ann. Neurol. 36 (1994) 100-103.
DOI Google Scholar
[25]

F.M. Corrigan, C.L. Wienburg, R.F. Shore, S.E. Daniel, D. Mann, Organochlorine insecticides in substantia nigra in Parkinson's disease, J. Toxicol. Environ. Health A 59 (2000) 229-234.
DOI Google Scholar
[26]

S. Costello, M. Cockburn, J. Bronstein, X. Zhang, B. Ritz, Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California, Am. J. Epidemiol. 169 (2009) 919-926.
DOI Google Scholar
[27]

C.M. Tanner, F. Kamel, G.W. Ross, J.A. Hoppin, S.M. Goldman, M. Korell, C. Marras, G.S. Bhudhikanok, M. Kasten, A.R. Chade, K. Comyns, M.B. Richards, C. Meng, B. Priestley, H.H. Fernandez, F. Cambi, D.M. Umbach, A. Blair, D.P. Sandler, J.W. Langston, Rotenone, paraquat, and Parkinson's disease, Environ. Health Perspect. 119 (2011) 866-872.
DOI Google Scholar
[28]

G. van Maele-Fabry, P. Hoet, F. Vilain, D. Lison, Occupational exposure to pesticides and Parkinson's disease: a systematic review and meta-analysis of cohort studies, Environ. Int. 46 (2012) 30-43.
DOI Google Scholar
[29]

H. Braak, K. Del Tredici, Potential pathways of abnormal tau and α-synuclein dissemination in sporadic Alzheimer's and Parkinson's diseases, Cold Spring Harb. Perspect. Biol. 8 (2016), pii: a023630.
DOI Google Scholar
[30]

K.L. Adams-Carr, J.P. Bestwick, S. Shribman, A. Lees, A. Schrag, A.J. Noyce, Constipation preceding Parkinson's disease: a systematic review and meta-analysis, J. Neurol. Neurosurg. Psychiatry 87 (2016) 710-716.
DOI Google Scholar
[31]

A. Mukherjee, A. Biswas, S.K. Das, Gut dysfunction in Parkinson's disease, World J. Gastroenterol. 22 (2016) 5742-5752.
DOI Google Scholar
[32]

E. Svensson, E. Horváth-Puhó, R.W. Thomsen, J.C. Djurhuus, L. Pedersen, P. Borghammer, H.T. Sørensen, Vagotomy and subsequent risk of Parkinson's disease, Ann. Neurol. 78 (2015) 522-529.
DOI Google Scholar
[33]

H. Reichmann, Modern treatment in Parkinson's disease, a personal approach, J. Neural Transm. 123 (2016) 73-80.
DOI Google Scholar
[34]

R. Dhall, D.L. Kreitzman, Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety, Neurology 86 (14 Suppl. 1) (2016) S13-S24.
DOI Google Scholar
[35]

C.D. Binde, I.F. Tvete, J. Gåsemyr, B. Natvig, M. Klemp, A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease, Br. J. Clin. Pharmacol. 84 (2018) 1917-1927.
DOI Google Scholar
[36]

K.W. Lange, Clinical pharmacology of dopamine agonists in Parkinson's disease, Drugs Aging 13 (1998) 381-389.
DOI Google Scholar
[37]

S. Fahn, The history of dopamine and levodopa in the treatment of Parkinson's disease, Mov. Disord. 23 (Suppl. 3) (2008) S497-S508.
DOI Google Scholar
[38]

M. Yamamoto, A.H.V. Schapira, Dopamine agonists in Parkinson's disease, Exp. Rev. Neurother. 8 (2008) 671-677.
DOI Google Scholar
[39]

K. Jellinger, Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts, Mov. Disord. 27 (2012) 8-30.
DOI Google Scholar
[40]

K.W. Lange, F.R. Wells, M.N. Rossor, P. Jenner, C.D. Marsden, Brain muscarinic receptors in Alzheimer's and Parkinson's diseases, Lancet 334 (1989) 1279.
DOI Google Scholar
[41]

K.W. Lange, F.R. Wells, M.N. Rossor, P. Jenner, C.D. Marsden, Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease, J. Neurol. Neurosurg. Psychiatry 54 (1991) 373-374.
DOI Google Scholar
[42]

P. Riederer, K.W. Lange, J. Kornhuber, W. Danielczyk, Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia, Arzneimittelforschung 42 (1992) 265-268.
Google Scholar
[43]

K.W. Lange, F.R. Wells, P. Jenner, C.D. Marsden, Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease, J. Neurochem. 60 (1993) 197-203.
DOI Google Scholar
[44]

K.W. Lange, J. Kornhuber, P. Riederer, Dopamine/glutamate interactions in Parkinson's disease, Neurosci. Biobehav. Rev. 21 (1997) 393-400.
DOI Google Scholar
[45]

J.M. Fearnley, A.J. Lees, Ageing and Parkinson's disease: substantia nigra regional selectivity, Brain 114 (1991) 2283-2301.
DOI Google Scholar
[46]

W.C. Koller, When does Parkinson's disease begin? Neurology 42 (Suppl. 4) (1992) 27-31.
Google Scholar
[47]

M.A. Hernan, B. Takkouche, F. Caamaño -Isorna, J.J. Gestal-Otero, A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Ann. Neurol. 52 (2002) 276-284.
DOI Google Scholar
[48]

A. Gaenslen, T. Gasser, D. Berg, Nutrition and the risk for Parkinson's disease: review of the literature, J. Neural Transm. 115 (2008) 703-713.
DOI Google Scholar
[49]

D.B. Calne, A. Eisen, E. McGeer, P. Spencer, Alzheimer's disease Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment?, Lancet 2 (1986) 1067-1070.
DOI Google Scholar
[50]
P.A. Cox, O.W. Sacks (2002) Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam, Neurology 58 (2002) 956-959.
DOI
[51]

A. Wang, Y. Lin, Y. Wu, D. Zhang, Macronutrients intake and risk of Parkinson's disease: a meta-analysis, Geriatr. Gerontol. Int. 15 (2015) 606-616.
DOI Google Scholar
[52]

L. Ishihara, C. Brayne, A systematic review of nutritional risk factors of Parkinson's disease, Nutr. Res. Rev. 18 (2005) 259-282.
DOI Google Scholar
[53]

K. Sääksjärvi, P. Knekt, A. Lundqvist, S. Männistö, M. Heliövaara, H. Rissanen, R. Järvinen, A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality, Br. J. Nutr. 109 (2013) 329-337.
DOI Google Scholar
[54]

W. Hellenbrand, H. Boeing, B.P. Robra, A. Seidler, P. Vieregge, P. Nischan, J. Joerg, W.H. Oertel, E. Schneider, G. Ulm, Diet and Parkinson's disease. Ⅱ: a possible role for the past intake of specific nutrients. Results from a self-administered food frequency questionnaire in a case–control study, Neurology 47 (1996) 644-650.
DOI Google Scholar
[55]

H. Chen, S.M. Zhang, M.A. Hernán, W.C. Willett, A. Ascherio, Diet and Parkinson's disease: a potential role of dairy products in men, Ann. Neurol. 52 (2002) 793-801.
DOI Google Scholar
[56]

L.K. Mischley, R.C. Lau, R.D. Bennett, Role of diet and nutritional supplements in Parkinson's disease progression, Oxid. Med. Cell Longev. 2017 (2017) 6405278.
DOI Google Scholar
[57]

M. Park, G.W. Ross, H. Petrovitch, L.R. White, K.H. Masaki, J.S. Nelson, C.M. Tanner, J.D. Curb, P.L. Blanchette, R.D. Abbott, Consumption of milk and calcium in midlife and the future risk of Parkinson disease, Neurology 64 (2005) 1047-1051.
DOI Google Scholar
[58]

H. Chen, E. O'Reilly, M.L. McCullough, C. Rodriguez, M.A. Schwarzschild, E.E. Calle, M.J. Thun, A. Ascherio, Consumption of dairy products and risk of Parkinson's disease, Am. J. Epidemiol. 165 (2007) 998-1006.
DOI Google Scholar
[59]

A. Kyrozis, A. Ghika, P. Stathopoulos, D. Vassilopoulos, D. Trichopoulos, A. Trichopoulou, Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece, Eur. J. Epidemiol. 28 (2013) 67-77.
DOI Google Scholar
[60]

K.C. Hughes, X. Gao, I.Y. Kim, M. Wang, M.G. Weisskopf, M.A. Schwarzschild, A. Ascherio, Intake of dairy foods and risk of Parkinson disease, Neurology 89 (2017) 46-52.
DOI Google Scholar
[61]

W. Jiang, C. Ju, H. Jiang, D. Zhang, Dairy foods intake and risk of Parkinson's disease: a dose–response meta-analysis of prospective cohort studies, Eur. J. Epidemiol. 29 (2014) 613-619.
DOI Google Scholar
[62]

A. Priyadarshi, S.A. Khuder, E.A. Schaub, S. Shrivastava, A meta-analysis of Parkinson's disease and exposure to pesticides, Neurotoxicology 21 (2000) 435-440.
Google Scholar
[63]

M.G. Weisskopf, P. Knekt, E.J. O'Reilly, J. Lyytinen, A. Reunanen, F. Laden, L. Altshul, A. Ascherio, Persistent organochlorine pesticides in serum and risk of Parkinson disease, Neurology 74 (2010) 1055-1061.
DOI Google Scholar
[64]

J.W. Davis, A. Grandinetti, C.I. Waslien, G.W. Ross, L.R. White, D.M. Morens, Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease, Am. J. Epidemiol. 144 (1996) 480-484.
DOI Google Scholar
[65]

L.M. de Lau, P.J. Koudstaal, A. Hofman, M.M. Breteler, Serum uric acid levels and the risk of Parkinson disease, Ann. Neurol. 58 (2005) 797-800.
DOI Google Scholar
[66]

M.G. Weisskopf, E. O'Reilly, H. Chen, M.A. Schwarzschild, A. Ascherio, Plasma urate and risk of Parkinson's disease, Am. J. Epidemiol. 166 (2007) 561-567.
DOI Google Scholar
[67]

X. Chen, G. Wu, M.A. Schwarzschild, Urate in Parkinson's disease: more than a biomarker? Curr. Neurol. Neurosci. Rep. 12 (2012) 367-375.
DOI Google Scholar
[68]

C. Shen, Y. Guo, W. Luo, C. Lin, M. Ding, Serum urate and the risk of Parkinson's disease: results from a meta-analysis, Can. J. Neurol. Sci. 40 (2013) 73-79.
DOI Google Scholar
[69]

X. Gao, E.J. O'Reilly, M.A. Schwarzschild, A. Ascherio, Prospective study of plasma urate and risk of Parkinson disease in men and women, Neurology 86 (2016) 520-526.
DOI Google Scholar
[70]

D.R. Garrel, M. Verdy, C. PetitClerc, C. Martin, D. Brulé, P. Hamet, Milk- and soy-protein ingestion: acute effect on serum uric acid concentration, Am. J. Clin. Nutr. 53 (1991) 665-669.
DOI Google Scholar
[71]

N. Dalbeth, S. Wong, G.D. Gamble, A. Horne, B. Mason, B. Pool, L. Fairbanks, F.M. McQueen, J. Cornish, I.R. Reid, K. Palmano, Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial, Ann. Rheum. Dis. 69 (2010) 1677-1682.
DOI Google Scholar
[72]

H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, G. Curhan, Purine-rich foods, dairy and protein intake, and the risk of gout in men, N. Engl. J. Med. 350 (2004) 1093-1103.
DOI Google Scholar
[73]

R.D. Abbott, G.W. Ross, H. Petrovitch, K.H. Masaki, L.J. Launer, J.S. Nelson, L.R. White, C.M. Tanner, Midlife milk consumption and substantia nigra neuron density at death, Neurology 86 (2016) 512-519.
DOI Google Scholar
[74]

Y. Gu, J.A. Luchsinger, Y. Stern, N. Scarmeas, Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease, J. Alzheimers Dis. 22 (2010) 483-492.
DOI Google Scholar
[75]

K.W. Lange, J. Guo, S. Kanaya, K.M. Lange, Y. Nakamura, S. Li, Mediterranean diet and Alzheimer's disease, Mov. Nutr. Health Dis. 3 (2019) 1.
DOI Google Scholar
[76]

X. Gao, H. Chen, T.T. Fung, G. Logroscino, M.A. Schwarzschild, F.B. Hu, A. Ascherio, Prospective study of dietary pattern and risk of Parkinson disease, Am. J. Clin. Nutr. 86 (2007) 1486-1494.
DOI Google Scholar
[77]

R.N. Alcalay, Y. Gu, H. Mejia-Santana, L. Cote, K.S. Marder, N. Scarmeas, The association between Mediterranean diet adherence and Parkinson's disease, Mov. Disord. 27 (2012) 771-774.
DOI Google Scholar
[78]

M.I. Maraki, M. Yannakoulia, M. Stamelou, L. Stefanis, G. Xiromerisiou, M.H. Kosmidis, E. Dardiotis, G.M. Hadjigeorgiou, P. Sakka, C.A. Anastasiou, E. Simopoulou, N. Scarmeas, Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease, Mov. Disord. 34 (2019) 48-57.
DOI Google Scholar
[79]

J. Chao, Y. Leung, M. Wang, R.C.C. Chang, Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease, Nutr. Rev. 70 (2012) 373-386.
DOI Google Scholar
[80]

N.G. Bazan, Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection, Mol. Aspects Med. 64 (2018) 18-33.
DOI Google Scholar
[81]

A. Ticinesi, T. Meschi, F. Lauretani, G. Felis, F. Franchi, C. Pedrolli, M. Barichella, G. Benati, S. Di Nuzzo, G.P. Ceda, M. Maggio, Nutrition and inflammation in older individuals: focus on vitamin D, n-3 polyunsaturated fatty acids and whey proteins, Nutrients 8 (2016) 186.
DOI Google Scholar
[82]

E.C. Hirsch, S. Hunot, Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 (2009) 382-397.
DOI Google Scholar
[83]

M.G. Tansey, M.S. Goldberg, Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention, Neurobiol. Dis. 37 (2010) 510-518.
DOI Google Scholar
[84]

P.C. Calder, Polyunsaturated fatty acids and inflammation, Prostaglandins Leukot. Essent. Fatty Acids 75 (2006) 197-202.
DOI Google Scholar
[85]

S.K. Orr, R.P. Bazinet, The emerging role of docosahexaenoic acid in neuroinflammation, Curr. Opin. Investig. Drugs 9 (2008) 735-743.
Google Scholar
[86]

S. Hong, K. Gronert, P.R. Devchand, R.L. Moussignac, C.N. Serhan, Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation, J. Biol. Chem. 278 (2003) 14677-14687.
DOI Google Scholar
[87]

N.G. Bazan, Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress, Brain Pathol. 15 (2005) 159-166.
DOI Google Scholar
[88]

M. Mogi, A. Togari, T. Kondo, Y. Mizuno, O. Komure, S. Kuno, H. Ichinose, T. Nagatsu, Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease, Neurosci. Lett. 270 (1999) 45-48.
DOI Google Scholar
[89]

K. Parain, M.G. Murer, Q. Yan, B. Faucheux, Y. Agid, E. Hirsch, R. Raisman-Vozari, Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra, Neuroreport 10 (1999) 557-561.
DOI Google Scholar
[90]

A. Lapillonne, S.D. Clarke, W.C. Heird, Polyunsaturated fatty acids and gene expression, Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 151-156.
DOI Google Scholar
[91]

C. Alves da Costa, F. Checler, Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell. Signal. 23 (2011) 963-968.
DOI Google Scholar
[92]

C. Julien, L. Berthiaume, A. Hadj-Tahar, A.H. Rajput, P.J. Bédard, T. Di Paolo, P. Julien, F. Calon, Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys, Neurochem. Int. 48 (2006) 404-414.
DOI Google Scholar
[93]

F. Calon, G. Cole, Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies, Prostaglandins Leukot. Essent. Fatty Acids 77 (2007) 287-293.
DOI Google Scholar
[94]

L.M. de Lau, M. Bornebroek, J.C. Witteman, A. Hofman, P.J. Koudstaal, M.M. Breteler, Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study, Neurology 64 (2005) 2040-2045.
DOI Google Scholar
[95]

M. Taghizadeh, O.R. Tamtaji, E. Dadgostar, R. Daneshvar Kakhaki, F. Bahmani, J. Abolhassani, M.H. Aarabi, E. Kouchaki, M.R. Memarzadeh, Z. Asemi, The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial, Neurochem. Int. 108 (2017) 183-189.
DOI Google Scholar
[96]

M. Bousquet, F. Calon, F. Cicchetti, Impact of ω-3 fatty acids in Parkinson's disease, Ageing Res. Rev. 10 (2011) 453-463.
DOI Google Scholar
[97]

C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, A. Lang, W. Langston, E. Melamed, W. Poewe, F. Stocchi, E. Tolosa, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N. Engl. J. Med. 361 (2009) 1268-1278.
DOI Google Scholar
[98]

N. Collins, A.P. Tighe, S.A. Brunton, P.M. Kris-Etherton, Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective, J. Am. Coll. Nutr. 27 (2008) 659-666.
DOI Google Scholar
[99]

J.P. Kesby, D.W. Eyles, T.H. Burne, J.J. McGrath, The effects of vitamin D on brain development and adult brain function, Mol. Cell Endocrinol. 347 (2011) 121-127.
DOI Google Scholar
[100]

D.W. Eyles, T.H.J. Burne, J.J. McGrath, Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease, Front. Neuroendocrinol. 34 (2013) 47-64.
DOI Google Scholar
[101]

A.K. Yeshokumar, D. Saylor, M.D. Kornberg, E.M. Mowry, Evidence for the importance of vitamin D status in neurologic conditions, Curr. Treat. Options Neurol. 17 (2015) 51.
DOI Google Scholar
[102]

D.W. Eyles, S. Smith, R. Kinobe, M. Hewison, J.J. McGrath, Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain, J. Chem. Neuroanat. 29 (2005) 21-30.
DOI Google Scholar
[103]

G.W. Ross, H. Petrovitch, R.D. Abbott, Serum vitamin D and risk of Parkinson's disease, Mov. Disord. 31 (2016) 933-935.
DOI Google Scholar
[104]

X. Luo, R. Ou, R. Dutta, Y. Tian, H. Xiong, H. Shang, Association between serum vitamin D levels and Parkinson's disease: a systematic review and meta-analysis, Front. Neurol. 9 (2018) 909.
DOI Google Scholar
[105]

M. Suzuki, M. Yoshioka, M. Hashimoto, M. Murakami, K. Kawasaki, M. Noya, D. Takahashi, M. Urashima, 25-Hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease, Mov. Disord. 27 (2012) 264-271.
DOI Google Scholar
[106]

Z. Lv, H. Qi, L. Wang, X. Fan, F. Han, H. Wang, S. Bi, Vitamin D status and Parkinson's disease: a systematic review and meta-analysis, Neurol. Sci. 35 (2014) 1723-1730.
DOI Google Scholar
[107]

P. Knekt, A. Kilkkinen, H. Rissanen, J. Marniemi, K. Sääksjärvi, M. Heliövaara, Serum vitamin D and the risk of Parkinson disease, Arch. Neurol. 67 (2010) 808-811.
DOI Google Scholar
[108]

S. Shrestha, P. Lutsey, A. Alonso, X. Huang, T. Mosley, H. Chen, Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk, Mov. Disord. 31 (2016) 972-978.
DOI Google Scholar
[109]

M. Suzuki, M. Yoshioka, M. Hashimoto, M. Murakami, M. Noya, D. Takahashi, M. Urashima, Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease, Am. J. Clin. Nutr. 97 (2013) 1004-1013.
DOI Google Scholar
[110]

L.M. Rimmelzwaan, N.M. van Schoor, H.W. Paul Lips, E.M.W. Berendse, Eekhoff, Systematic review of the relationship between vitamin D and Parkinson's disease, J. Parkinsons Dis. 6 (2016) 29-37.
DOI Google Scholar
[111]

E. Reynolds, Vitamin B12, folic acid, and the nervous system, Lancet Neurol. 5 (2006) 949-960.
DOI Google Scholar
[112]

N. Kumar, Neurologic presentations of nutritional deficiencies, Neurol. Clin. 28 (2010) 107-170.
DOI Google Scholar
[113]

G. Sechi, E. Sechi, C. Fois, N. Kumar, Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults, Nutr. Rev. 2016 (2016) 281-300.
DOI Google Scholar
[114]

W. Kuhn, R. Roebroek, H. Blom, D. van Oppenraaij, T. Müller, Hyperhomocysteinaemia in Parkinson's disease, J. Neurol. 245 (1998) 811-812.
DOI Google Scholar
[115]

S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B. D'Agostino, P.W. Wilson, P.A. Wolf, Plasma homocysteine as a risk factor for dementia and Alzheimer's disease, N. Engl. J. Med. 346 (2002) 476-483.
DOI Google Scholar
[116]

R.B. Postuma, A.E. Lang, Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 63 (2004) 886-891.
DOI Google Scholar
[117]

Z. Todorović, E. Dzoljić, I. Novaković, D. Mirković, R. Stojanović, Z. Nesić, M. Krajinović, M. Prostran, V. Kostić, Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy, J. Neurol. Sci. 248 (2006) 56-61.
DOI Google Scholar
[118]

M.C. Rodriguez-Oroz, P.M. Lage, J. Sanchez-Mut, I. Lamet, J. Pagonabarraga, J.B. Toledo, D. García-Garcia, P. Clavero, L. Samaranch, C. Irurzun, J.M. Matsubara, J. Irigoien, E. Bescos, J. Kulisevsky, J. Pérez-Tur, J.A. Obeso, Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study, Mov. Disord. 24 (2009) 1437-1444.
DOI Google Scholar
[119]

W. Duan, B. Ladenheim, R.G. Cutler, I.I. Kruman, J.L. Cadet, M.P. Mattson, Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease, J. Neurochem. 80 (2002) 101-110.
DOI Google Scholar
[120]

I.I. Kruman, C. Culmsee, S.L. Chan, Y. Kruman, Z. Guo, L. Penix, M.P. Mattson, Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity, J. Neurosci. 20 (2000) 6920-6926.
DOI Google Scholar
[121]

S.A. Lipton, W.K. Kim, Y.B. Choi, S. Kumar, D.M. D'Emilia, P.V. Rayudu, D.R. Arnelle, J.S. Stamler, Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor, Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5923-5928.
DOI Google Scholar
[122]

H. Baker, O. Frank, T. Chen, S. Feingold, B. DeAngelis, E. Baker, Vitamin content of some normal human brain segments, J. Neurosci. Res. 11 (1984) 419-435.
DOI Google Scholar
[123]

H. Yamashita, Y.X. Zhang, S. Nakamura, The effects of thiamin and its phosphate esters on dopamine release in the rat striatum, Neurosci. Lett. 158 (1993) 229-231.
DOI Google Scholar
[124]

q. Luong, L.T.H. Nguyen, The beneficial role of thiamine in Parkinson disease, CNS Neurosci. Ther. 19 (2013) 461-468.
DOI Google Scholar
[125]

L.M. de Lau, P.J. Koudstaal, J.C. Witteman, A. Hofman, M.M. Breteler, Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease, Neurology 67 (2006) 315-318.
DOI Google Scholar
[126]

L. Shen, Associations between B vitamins and Parkinson's disease, Nutrients 7 (2015) 7197-7208.
DOI Google Scholar
[127]

A. Costantini, M.I. Pala, E. Grossi, S. Mondonico, L.E. Cardelli, C. Jenner, S. Proietti, M. Colangeli, R. Fancellu, Long-term treatment with high-dose thiamine in Parkinson disease: an open-label pilot study, J. Altern. Complement. Med. 21 (2015) 740-747.
DOI Google Scholar
[128]

A. Costantini, R. Fancellu, An open-label pilot study with high-dose thiamine in Parkinson's disease, Neural Regen. Res. 11 (2016) 406-407.
DOI Google Scholar
[129]

C.W. Olanow, A radical hypothesis for neurodegeneration, Trends Neurosci. 16 (1993) 439-444.
DOI Google Scholar
[130]

M.F. Beal, Mitochondria, oxidative damage, and inflammation in Parkinson's disease, Ann. N. Y. Acad. Sci. 991 (2003) 120-131.
DOI Google Scholar
[131]

H. Sies, W. Stahl, A.R. Sundquist, Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids, Ann. N. Y. Acad. Sci. 669 (1992) 7-20.
DOI Google Scholar
[132]

C.R. Burkhardt, H.K. Weber, Parkinson's disease: a chronic, low-grade antioxidant deficiency? Med. Hypotheses 43 (1994) 111-114.
DOI Google Scholar
[133]

A. Takeda, O.P. Nyssen, A. Syed, E. Jansen, B. Bueno-de-Mesquita, V. Gallo, Vitamin A and carotenoids and the risk of Parkinson's disease: a systematic review and meta-analysis, Neuroepidemiology 42 (2014) 25-38.
DOI Google Scholar
[134]

K.C. Hughes, X. Gao, I.Y. Kim, E. Rimm, M. Wang, M.G. Weisskopf, M.A. Schwarzschild, A. Ascherio, Intake of antioxidant vitamins and risk of Parkinson's disease, Mov. Disord. 31 (2016) 1909-1914.
DOI Google Scholar
[135]

J.A. Joseph, B. Shukitt-Hale, G. Casadesus, Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds, Am. J. Clin. Nutr. 81 (2005), 313S–316S.
DOI Google Scholar
[136]

K.W. Lange, Red wine, resveratrol, and Alzheimer's disease, Mov. Nutr. Health Dis. 2 (2018) 31-38.
Google Scholar
[137]

K.W. Lange, S. Li, Resveratrol, pterostilbene and dementia, BioFactors 44 (2018) 83-90.
DOI Google Scholar
[138]
A.S. Darvesh, M. McClure, P. Sadana, C. Paxos, W.J. Geldenhuys, J.D. Lambert, T.M. Haqqi, J.R. Richardson, Neuroprotective properties of dietary polyphenols in Parkinson's disease, in: T. Farooqui, A.A. Farooqui (Eds.), Neuroprotective Effects of Phytochemicals in Neurological Disorders, Wiley, 2017, pp. 243–263.
DOI
[139]

M. Kujawska, J. Jodynis-Liebert, Polyphenols in Parkinson's disease: a systematic review of in vivo studies, Nutrients 10 (2018) 642.
DOI Google Scholar
[140]

X. Gao, A. Cassidy, M.A. Schwarzschild, E.B. Rimm, A. Ascherio, Habitual intake of dietary flavonoids and risk of Parkinson disease, Neurology 78 (2012) 1138-1145.
DOI Google Scholar
[141]

D. Dutta, K.P. Mohanakumar, Tea and Parkinson's disease: constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits, Neurochem. Int. 89 (2015) 181-190.
DOI Google Scholar
[142]

D.K. Chan, G.D. Mellick, W.T. Hung, J. Woo, Genetic and environmental risk factors and their interactions for Parkinson's disease in a Chinese population, J. Clin. Neurosci. 10 (2003) 313-315.
DOI Google Scholar
[143]

H. Checkoway, K. Powers, T. Smith-Weller, G.M. Franklin, , P.D. Swanson, Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake, Am. J. Epidemiol. 155 (2002) 732-738.
DOI Google Scholar
[144]

E.K. Tan, C. Tan, S.M. Fook-Chong, S.Y. Lum, A. Chai, H. Chung, H. Shen, Y. Zhao, M.L. Teoh, Y. Yih, R. Pavanni, V.R. Chandran, M.C. Wong, Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese, J. Neurol. Sci. 216 (2003) 163-167.
DOI Google Scholar
[145]

L.C. Tan, W.P. Koh, J.M. Yuan, R. Wang, W.L. Au, J.H. Tan, E.K. Tan, M.C. Yu, Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study, Am. J. Epidemiol. 167 (2008) 553-560.
DOI Google Scholar
[146]

B. Kandinov, N. Giladi, A.D. Korczyn, Smoking and tea consumption delay onset of Parkinson's disease, Parkinsonism Relat. Disord. 15 (2009) 41-46.
DOI Google Scholar
[147]

F.J. Li, H.F. Ji, L. Shen, A meta-analysis of tea drinking and risk of Parkinson's disease, Sci. World J. 2012 (2012) 923464.
DOI Google Scholar
[148]

M.F. Beal, R.T. Matthews, A. Tieleman, C.W. Shults, Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1, 2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice, Brain Res. 783 (1998) 109-114.
DOI Google Scholar
[149]

C. Cleren, L. Yang, B. Lorenzo, N.Y. Calingasan, A. Schomer, A. Sireci, E.J. Wille, M.F. Beal, Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism, J. Neurochem. 104 (2008) 1613-1621.
DOI Google Scholar
[150]

C.W. Shults, Therapeutic role of coenzyme Q(10) in Parkinson's disease, Pharmacol. Ther. 107 (2005) 120-130.
DOI Google Scholar
[151]

L.K. Mischley, J. Allen, R. Bradley, Coenzyme Q10 deficiency in patients with Parkinson's disease, J. Neurol. Sci. 318 (2012) 72-75.
DOI Google Scholar
[152]

C.W. Shults, D. Oakes, K. Kieburtz, M.F. Beal, R. Haas, S. Plumb, J.L. Juncos, J. Nutt, I. Shoulson, J. Carter, K. Kompoliti, J.S. Perlmutter, S. Reich, M. Stern, R.L. Watts, R. Kurlan, E. Molho, M. Harrison, M. Lew, Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline, Arch. Neurol. 59 (2002) 1541-1550.
DOI Google Scholar
[153]

A. Negida, A. Menshawy, G. El Ashal, Y. Elfouly, Y. Hani, Y. Hegazy, S. El ghonimy, S. Fouda, Y. Rashad, Coenzyme Q10 for patients with Parkinson's disease: a systematic review and meta-analysis, CNS Neurol. Disord. Drug Targets 15 (2016) 45-53.
DOI Google Scholar
[154]

Z.G. Zhu, M.X. Sun, W.L. Zhang, W.W. Wang, Y.M. Jin, C. Xie, The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials, Neurol. Sci. 38 (2017) 215-224.
DOI Google Scholar
[155]
Food U.S. Drug Administration, Medical Foods Guidance Documents & Regulatory Information, 2019, Available from https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/default.htm (accessed 15.01.19).
[156]
The Commission of the European Communities, Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes, Official Journal L 091 07/04/1999, 1999, pp. 0029–0036, Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31999L0021:EN:HTML (accessed 15.01.19).
[157]

K.W. Lange, K.M. Lange, E. Makulska-Gertruda, Y. Nakamura, A. Reissmann, S. Kanaya, J. Hauser, Ketogenic diets and Alzheimer's disease, Food Sci. Hum. Wellness 6 (2017) 1-9.
DOI Google Scholar
[158]

K.W. Lange, J. Guo, S. Kanaya, K.M. Lange, Y. Nakamura, Shiming Li, Medical foods in Alzheimer's disease, Food Sci. Hum. Wellness 8 (2019) 1-7.
DOI Google Scholar
[159]

D. Wlodarek, Role of ketogenic diets in neurodegenerative diseases (Alzheimer's disease and Parkinson's disease), Nutrients 11 (2019) 169.
DOI Google Scholar
[160]

S.E. Seidl, J.A. Santiago, H. Bilyk, J.A. Potashkin, The emerging role of nutrition in Parkinson's disease, Front. Aging Neurosci. 6 (2014) 36.
DOI Google Scholar
[161]

R.J. Wurtman, J.J. Wurtman, M.M. Regan, J.M. McDermott, R.H. Tsay, J.J. Breu, Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios, Am. J. Clin. Nutr. 77 (2003) 128-132.
DOI Google Scholar
[162]

K. Murakami, Y. Miyake, S. Sasaki, K. Tanaka, W. Fukushima, C. Kiyohara, Y. Tsuboi, T. Yamada, T. Oeda, T. Miki, N. Kawamura, N. Sakae, H. Fukuyama, Y. Hirota, M. Nagai, Fukuoka Kinki Parkinson's Disease Study, Dietary glycemic index is inversely associated with the risk of Parkinson's disease: a case–control study in Japan, Nutrition 26 (2010) 515-521.
DOI Google Scholar
[163]

R. Krikorian, M.D. Shidler, K. Dangelo, S.C. Couch, S.C. Benoit, D.J. Clegg, Dietary ketosis enhances memory in mild cognitive impairment, Neurobiol. Aging 33 (2012) 425. e19–425. e27.
DOI Google Scholar
[164]

W.D. Parker Jr., J.K. Parks, R.H. Swerdlow, Complex I deficiency in Parkinson's disease frontal cortex, Brain Res. 1189 (2008) 215-216.
DOI Google Scholar
[165]

K. Tieu, C. Perier, C. Caspersen, P. Teismann, D.C. Wu, S.D. Yan, A. Naini, M. Vila, V. Jackson-Lewis, R. Ramasamy, S. Przedborski, D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease, J. Clin. Invest. 112 (2003) 892-901.
DOI Google Scholar
[166]

K.J. Bough, J. Wetherington, B. Hassel, J.F. Pare, J.W. Gawryluk, J.G. Greene, R. Shaw, Y. Smith, J.D. Geiger, R.J. Dingledine, Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet, Ann. Neurol. 60 (2006) 223-235.
DOI Google Scholar
[167]

T.B. VanItallie, C. Nonas, A. Di Rocco, K. Boyar, K. Hyams, S.B. Heymsfield, Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study, Neurology 64 (2005) 728-730.
DOI Google Scholar
[168]

M.C.L. Phillips, D.K.J. Murtagh, L.J. Gilbertson, F.J.S. Asztely, C.D.P. Lynch, Low-fat versus ketogenic diet in Parkinson's disease: a pilot randomized controlled trial, Mov. Disord. 33 (2018) 1306-1314.
DOI Google Scholar
[169]

A.M. Malek, G.G. Goss, L. Jiang, S. Izumo, S.L. Alper, Mannitol at clinical concentrations activates multiple signaling pathways and induces apoptosis in endothelial cells, Stroke 29 (1998) 2631-2640.
DOI Google Scholar
[170]

G.Y. Pan, X.D. Liu, G.Q. Liu, Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats, Acta Pharmacol. Sin. 21 (2000) 613-616.
Google Scholar
[171]

D.J. Begley, Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmacol. Ther. 104 (2004) 29-45.
DOI Google Scholar
[172]

X. Liu, C. Chen, Strategies to optimize brain penetration in drug discovery, Curr. Opin. Drug Discov. Devel. 8 (2005) 505-512.
Google Scholar
[173]

L.M. Holthauzen, D.W. Bolen, Mixed osmolytes: the degree to which one osmolyte affects the protein stabilizing ability of another, Protein Sci. 16 (2007) 293-298.
DOI Google Scholar
[174]

R.S. Rajan, K. Tsumoto, M. Tokunaga, H. Tokunaga, Y. Kita, T. Arakawa, Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases, Curr. Med. Chem. 18 (2011) 1-15.
DOI Google Scholar
[175]

T.K. Chaudhuri, S. Paul, Protein-misfolding diseases and chaperone-based therapeutic approaches, FEBS J. 273 (2006) 1331-1349.
DOI Google Scholar
[176]

M.B. Feany, W.W. Bender, A Drosophila model of Parkinson's disease, Nature 404 (2000) 394-398.
DOI Google Scholar
[177]

R. Shaltiel-Karyo, M. Frenkel-Pinter, E. Rockenstein, C. Patrick, M. Levy-Sakin, A. Schiller, N. Egoz-Matia, E. Masliah, D. Segal, E. Gazit, A blood–brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor, a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD), J. Biol. Chem. 288 (2013) 17579-17588.
DOI Google Scholar
[178]

E. Rockenstein, M. Mallory, M. Hashimoto, D. Song, C.W. Shults, I. Lang, E. Masliah, Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters, J. Neurosci. Res. 68 (2002) 568-578.
DOI Google Scholar
[179]

D. McCammon, Medical food to stop the progression of Parkinson's disease, Adv. Parkinson Dis. 3 (2014) 10-13.
DOI Google Scholar
[180]

R.G. Mattace, R. Russo, A. Calignano, R. Meli, Palmitoylethanolamide in CNS health and disease, Pharmacol. Res. 86 (2014) 32-41.
DOI Google Scholar
[181]

E. Esposito, D. Impellizzeri, E. Mazzon, I. Paterniti, S. Cuzzocrea, Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease, PLoS One 7 (2012) e41880.
DOI Google Scholar
[182]

C. Avagliano, R. Russo, C. De Caro, C. Cristiano, G. La Rana, G. Piegari, O. Paciello, R. Citraro, E. Russo, G. De Sarro, R. Meli, G. Mattace Raso, A. Calignano, Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: in vivo and in vitro evidence, Pharmacol. Res. 13 (2016) 276-289.
DOI Google Scholar
[183]

C. Caltagirone, C. Cisari, C. Schievano, R. Di Paola, M. Cordaro, G. Bruschetta, E. Esposito, S. Cuzzocrea, Stroke Study Group, Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man, Transl. Stroke Res. 7 (2016) 54-69.
DOI Google Scholar
[184]

N.S. Orefice, M. Alhouayek, A. Carotenuto, S. Montella, F. Barbato, A. Comelli, A. Calignano, G.G. Muccioli, G. Orefice, Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis, Neurotherapeutics 13 (2016) 428-438.
DOI Google Scholar
[185]

S. Brotini, C. Schievano, L. Guidi, Ultra-micronized palmitoethanolamide: an efficacious adjuvant therapy for Parkinson's disease, CNS Neurol. Disord. Drug Targets 16 (2017) 705-713.
DOI Google Scholar
[186]

S.D. Skaper, L. Facci, M. Fusco, M.F. Della Valle, M. Zusso, B. Costa, P. Giusti, Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain, Inflammopharmacology 22 (2014) 79-94.
DOI Google Scholar
[187]

A. Keshavarzian, S.J. Green, P.A. Engen, R.M. Voigt, A. Naqib, C.B. Forsyth, E. Mutlu, K.M. Shannon, Colonic bacterial composition in Parkinson's disease, Mov. Disord. 30 (2015) 1351-1360.
DOI Google Scholar
[188]

F. Scheperjans, V. Aho, P.A.B. Pereira, K. Koskinen, L. Paulin, E. Pekkonen, E. Haapaniemi, S. Kaakkola, J. Eerola-Rautio, M. Pohja, E. Kinnunen, K. Murros, P. Auvinen, Gut microbiota are related to Parkinson's disease and clinical phenotype, Mov. Disord. 30 (2015) 350-358.
DOI Google Scholar
[189]

A. Becker, K. Faßbender, W.H. Oertel, M.M. Unger, A punch in the gut–intestinal inflammation links environmental factors to neurodegeneration in Parkinson's disease, Parkinsonism Relat. Disord. (2018), pii: S1353-8020(18)30428-0.
Google Scholar
[190]

J.S. Bell, J.I. Spencer, R.L. Yates, S.A. Yee, B.M. Jacobs, G.C. DeLuca, Invited Review: From nose to gut – the role of the microbiome in neurological disease, Neuropathol. Appl. Neurobiol. (2018), http://dx.doi.org/10.1111/nan.12520.
DOI Google Scholar
[191]

C.N. Heiss, L.E. Olofsson, The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system, J. Neuroendocrinol. (2019) e12684.
DOI Google Scholar
[192]

S. Grenham, G. Clarke, J.F. Cryan, T.G. Dinan, Brain–gut–microbe communication in health and disease, Front. Physiol. 2 (2011) 94.
DOI Google Scholar
[193]

Y.E. Borre, R.D. Moloney, G. Clarke, T.G. Dinan, J.F. Cryan, The impact of microbiota on brain and behavior: mechanisms & therapeutic potential, Adv. Exp. Med. Biol. 817 (2014) 373-403.
DOI Google Scholar
[194]

P. Forsythe, J. Bienenstock, W.A. Kunze, Vagal pathways for microbiome–brain–gut axis communication, Adv. Exp. Med. Biol. 817 (2014) 115-133.
DOI Google Scholar
[195]

M.M. Unger, J. Spiegel, K.U. Dillmann, D. Grundmann, H. Philippeit, J. Burmann, K. Fassbender, A. Schwiertz, K.H. Schäfer, Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls, Parkinsonism Relat. Disord. 32 (2016) 66-72.
DOI Google Scholar
[196]

E.M. Hill-Burns, J.W. Debelius, J.T. Morton, W.T. Wissemann, M.R. Lewis, Z.D. Wallen, S.D. Peddada, S.A. Factor, E. Molho, C.P. Zabetian, R. Knight, H. Payami, Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome, Mov. Disord. 32 (2017) 739-749.
DOI Google Scholar
[197]

I. Peter, M. Dubinsky, S. Bressman, A. Park, C. Lu, N. Chen, A. Wang, Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease, JAMA Neurol. 75 (2018) 930-946.
DOI Google Scholar
[198]

A. Mulak, S. Budrewicz, M. Panek-Jeziorna, M. Koszewicz, M. Jasinska, B. Marczak- Karpina, K. Slotwinski, R. Podemski, L. Paradowski, Fecal Biomarkers of gut inflammation and intestinal barrier dysfunction in Parkinson's disease, Gastroenterology 152 (2017) S924.
DOI Google Scholar
[199]

A. Schwiertz, J. Spiegel, U. Dillmann, D. Grundmann, J. Burmann, K. Fassbender, K.H. Schäfer, M.M. Unger, Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease, Parkinsonism Relat. Disord. 50 (2018) 104-107.
DOI Google Scholar
[200]

D. Devos, T. Lebouvier, B. Lardeux, M. Biraud, T. Rouaud, H. Pouclet, E. Coron, S. Bruley des Varannes, P. Naveilhan, J.M. Nguyen, M. Neunlist, P. Derkinderen, Colonic inflammation in Parkinson's disease, Neurobiol. Dis. 50 (2013) 42-48.
DOI Google Scholar
[201]

S.M. Dobbs, R.J. Dobbs, C. Weller, A. Charlett, A. Augustin, D. Taylor, M.A. Ibrahim, I. Bjarnason, Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and comorbidities: role of gastrointestinal microbiota, J. Neurovirol. 22 (2016) 22-32.
DOI Google Scholar
[202]

M.C. Houser, J. Chang, S.A. Factor, E.S. Molho, C.P. Zabetian, E.M. Hill-Burns, H. Payami, V.S. Hertzberg, M.G. Tansey, Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease, Mov. Disord. 33 (2018) 793-804.
DOI Google Scholar
[203]

T.C. Fung, C.A. Olson, E.Y. Hsiao, Interactions between the microbiota, immune and nervous systems in health and disease, Nat. Neurosci. 20 (2017) 145-155.
DOI Google Scholar
[204]

A. Ananthaswamy, Faecal transplant eases symptoms of Parkinson's disease, New Scientist 209 (2011) 8-9.
DOI Google Scholar
[205]

C. Hill, F. Guarner, G. Reid, G.R. Gibson, D.J. Merenstein, B. Pot, L. Morelli, R.B. Canani, H.J. Flint, S. Salminen, P.C. Calder, M.E. Sanders, Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat. Rev. Gastroenterol. Hepatol. 11 (2014) 506-514.
DOI Google Scholar
[206]

P. Bercik, A.J. Park, D. Sinclair, A. Khoshdel, J. Lu, X. Huang, Y. Deng, P.A. Blennerhassett, M. Fahnestock, D. Moine, B. Berger, J.D. Huizinga, W. Kunze, P.G. McLean, G.E. Bergonzelli, S.M. Collins, E.F. Verdu, The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication, Neurogastroenterol. Motil. 23 (2011) 1132-1139.
DOI Google Scholar
[207]

P. Bercik, E. Denou, J. Collins, W. Jackson, J. Lu, J. Jury, Y. Deng, P. Blennerhassett, J. Macri, K.D. McCoy, E.F. Verdu, S.M. Collins, The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice, Gastroenterology 141 (2011) 599-609.
DOI Google Scholar
[208]

H.M. Savignac, B. Kiely, T.G. Dinan, J.F. Cryan, Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice, Neurogastroenterol. Motil. 26 (2014) 1615-1627.
DOI Google Scholar
[209]

B. Sánchez, S. Delgado, A. Blanco-Míguez, A. Lourenço, M. Gueimonde, A. Margolles, Probiotics, gut microbiota, and their influence on host health and disease, Mol. Nutr. Food Res. 61 (2017) 1600-2240.
DOI Google Scholar
[210]

M. Barichella, C. Pacchetti, C. Bolliri, E. Cassani, L. Iorio, C. Pusani, G. Pinelli, G. Privitera, I. Cesari, S.A. Faierman, R. Caccialanza, G. Pezzoli, E. Cereda, Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT, Neurology 87 (2016) 1274-1280.
DOI Google Scholar
[211]

P. Perez-Pardo, T. Kliest, H.B. Dodiya, L.M. Broersen, J. Garssen, A. Keshavarzian, A.D. Kraneveld, The gut–brain axis in Parkinson's disease: Possibilities for food-based therapies, Eur. J. Pharmacol. 817 (2017) 86-95.
DOI Google Scholar
[212]

O.R. Tamtaji, M. Taghizadeh, R.D. Kakhaki, E. Kouchaki, F. Bahmani, S. Borzabadi, S. Oryan, A. Mafi, Z. Asemi, Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial, Clin. Nutr. 2018 (2018), pii: S0261-5614(18)30203-6.
Google Scholar
[213]

J.M. Taylor, B.S. Main, P.J. Crack, Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease, Neurochem. Int. 62 (2013) 803-819.
DOI Google Scholar
[214]

A. Parashar, M. Udayabanu, Gut microbiota: implications in Parkinson's disease, Parkinsonism Relat. Disord. 38 (2017) 7.
DOI Google Scholar
[215]

M. Lyte, Microbial endocrinology in the microbiome–gut–brain axis: how bacterial production and utilization of neurochemicals influence behavior, PLoS Pathog. 9 (2013) e1003726.
DOI Google Scholar
[216]

M. Lyte, Microbial endocrinology and the microbiota–gut–brain axis, Adv. Exp. Med. Biol. 817 (2014) 3-24.
DOI Google Scholar
[217]

R. Valladares, L. Bojilova, A.H. Potts, E. Cameron, C. Gardner, G. Lorca, C.F. Gonzalez, Lactobacillus johnsonii inhibits indoleamine 2,3-dioxygenase and alters tryptophan metabolite levels in BioBreeding rats, FASEB J. 27 (2013) 1711-1720.
DOI Google Scholar
[218]

H. Sadrzadeh-Yeganeh, I. Elmadfa, A. Djazayery, M. Jalali, R. Heshmat, M. Chamary, The effects of probiotic and conventional yoghurt on lipid profile in women, Br. J. Nutr. 103 (2010) 1778-1783.
DOI Google Scholar
[219]

A. Kinoshita, H. Onoda, N. Imai, H. Nishino, H. Tajiri, C-reactive protein as a prognostic marker in patients with hepatocellular carcinoma, Hepatogastroenterology 62 (2015) 966-970.
Google Scholar
[220]

J.A. Driver, A. Smith, J.E. Buring, J.M. Gaziano, T. Kurth, G. Logroscino, Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease, Diabetes Care 31 (2008) 2003-2005.
DOI Google Scholar
[221]

F.B. Hu, Dietary pattern analysis: a new direction in nutritional epidemiology, Curr. Opin. Lipidol. 13 (2002) 3-9.
DOI Google Scholar
[222]

Y. Gu, N. Scarmeas, Dietary patterns in Alzheimer's disease and cognitive aging, Curr. Alzheimer Res. 8 (2011) 510-519.
DOI Google Scholar
[223]

C. Marras, A. Lang, Parkinson's disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry 84 (2013) 409-415.
DOI Google Scholar
[224]

J. Jankovic, M. McDermott, J. Carter, S. Gauthier, C. Goetz, L. Golbe, S. Huber, W. Koller, C. Olanow, I. Shoulson, M. Stern, C. Tanner, W. Weiner, Parkinson Study Group, Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group, Neurology 40 (1990) 1529-1534.
DOI Google Scholar
[225]

M.H. Mark, Lumping and splitting the Parkinson Plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration, Neurol. Clin. 19 (2001) 607-627.
DOI Google Scholar
[226]

T.W. Robbins, M. James, A.M. Owen, K.W. Lange, A.J. Lees, P.N. Leigh, C.D. Marsden, N.P. Quinn, B.A. Summers, Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction, J. Neurol. Neurosurg. Psychiatry 57 (1994) 79-88.
DOI Google Scholar
[227]

K.W. Lange, O. Tucha, G.L. Alders, M. Preier, I. Csoti, B. Merz, G. Mark, B. Herting, F. Fornadi, H. Reichmann, P. Vieregge, K. Reiners, G. Becker, M. Naumann, Differentiation of parkinsonian syndromes according to differences in executive functions, J. Neural Transm. 110 (2003) 983-995.
DOI Google Scholar
[228]

W.R.G. Gibb, A.J. Lees, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J. Neurol. Neurosurg. Psychiatry 51 (1988) 745-752.
DOI Google Scholar
[229]

A. Siderowf, A.E. Lang, Premotor Parkinson's disease: concepts and definitions, Mov. Disord. 27 (2012) 608-616.
DOI Google Scholar
[230]

G.W. Ross, H. Petrovitch, R.D. Abbott, J. Nelson, W. Markesbery, D. Davis, J. Hardman, L. Launer, K. Masaki, C.M. Tanner, L.R. White, Parkinsonian signs and substantia nigra neuron density in decedent elders without PD, Ann. Neurol. 56 (2004) 532-539.
DOI Google Scholar
[231]

B. Berg, G. Becker, B. Zeiler, O. Tucha, E. Hofmann, M. Preier, P. Benz, K. Reiners, K.W. Lange, Vulnerability of the nigrostriatal system as detected by transcranial ultrasound, Neurology 53 (1999) 1026-1031.
DOI Google Scholar
[232]

P. Ruprecht-Dörfler, D. Berg, O. Tucha, P. Benz, M. Meier-Meitinger, G.L. Alders, K.W. Lange, G. Becker, Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease, Neuroimage 18 (2003) 416-422.
DOI Google Scholar
[233]

K. Stiasny-Kolster, Y. Doerr, J.C. Möller, H. Höffken, T.M. Behr, W.H. Oertel, G. Mayer, Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT, Brain 128 (2005) 126-137.
DOI Google Scholar
[234]

A. Heintz-Buschart, U. Pandey, T. Wicke, F. Sixel-Döring, A. Janzen, E. Sittig-Wiegand, C. Trenkwalder, W.H. Oertel, B. Mollenhauer, P. Wilmes, The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder, Mov. Disord. 33 (2018) 88-98.
DOI Google Scholar
[235]

M.F. Sun, Y.Q. Shen, Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease, Ageing Res. Rev. 45 (2018) 53-61.
DOI Google Scholar
[236]

M.P. Mattson, Gene–diet interactions in brain aging and neurodegenerative disorders, Ann. Intern. Med. 139 (2003) 441-444.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 05 March 2019
Revised: 11 March 2019
Accepted: 13 March 2019
Published: 28 March 2019
Issue date: June 2019

Copyright

© 2019 “Society information”.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return